14.21
2.46%
-0.405
Caredx Inc stock is currently priced at $14.21, with a 24-hour trading volume of 509.68K.
It has seen a -2.46% decreased in the last 24 hours and a -6.50% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $14.96 pivot point. If it approaches the $13.85 support level, significant changes may occur.
Previous Close:
$14.61
Open:
$14.27
24h Volume:
509.68K
Market Cap:
$725.10M
Revenue:
$280.32M
Net Income/Loss:
$-190.28M
P/E Ratio:
-9.1058
EPS:
-1.56
Net Cash Flow:
$-27.63M
1W Performance:
-6.31%
1M Performance:
-6.50%
6M Performance:
+31.22%
1Y Performance:
+82.46%
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
3260 Bayshore Boulevard, Brisbane, CA
Caredx Inc Stock (CDNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
Apr-25-22 | Initiated | Stephens | Overweight |
Jul-20-21 | Resumed | BTIG Research | Buy |
Jun-03-21 | Initiated | Goldman | Buy |
Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
Jun-26-20 | Initiated | BTIG Research | Buy |
Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
Oct-01-19 | Resumed | Craig Hallum | Buy |
May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
Feb-15-19 | Initiated | Jefferies | Buy |
Oct-23-18 | Resumed | Raymond James | Strong Buy |
Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
Nov-27-17 | Initiated | H.C. Wainwright | Buy |
Jun-14-16 | Reiterated | Mizuho | Buy |
Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Sep-25-15 | Initiated | Craig Hallum | Buy |
Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
A new trading data show Caredx Inc (CDNA) is showing positive returns. – Sete News - SETE News
SETE News
CareDx (NASDAQ:CDNA) Downgraded by StockNews.com to Hold - MarketBeat
MarketBeat
CareDx (NASDAQ:CDNA) Lowered to Hold at StockNews.com - Defense World
Defense World
CareDx (NASDAQ:CDNA) Shares Down 4.1% - MarketBeat
MarketBeat
CareDx (NASDAQ:CDNA) Trading Down 4.1% - MarketBeat
MarketBeat
Caredx Inc (CDNA) did well last session? – US Post News - US Post News
US Post News
Caredx Inc Stock (CDNA) Financials Data
Caredx Inc (CDNA) Revenue 2024
CDNA reported a revenue (TTM) of $280.32 million for the quarter ending December 31, 2023, a -12.89% decline year-over-year.
Caredx Inc (CDNA) Net Income 2024
CDNA net income (TTM) was -$190.28 million for the quarter ending December 31, 2023, a -148.37% decrease year-over-year.
Caredx Inc (CDNA) Cash Flow 2024
CDNA recorded a free cash flow (TTM) of -$27.63 million for the quarter ending December 31, 2023, a +44.27% increase year-over-year.
Caredx Inc (CDNA) Earnings per Share 2024
CDNA earnings per share (TTM) was -$3.53 for the quarter ending December 31, 2023, a -145.14% decline year-over-year.
Caredx Inc Stock (CDNA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Maag Peter | Director |
Apr 29 '24 |
Option Exercise |
5.27 |
13,281 |
69,991 |
327,264 |
Seeto Reginald | See Remarks |
Oct 02 '23 |
Sale |
6.91 |
2,818 |
19,483 |
479,164 |
Seeto Reginald | See Remarks |
Sep 05 '23 |
Sale |
9.49 |
2,819 |
26,762 |
481,982 |
Seeto Reginald | See Remarks |
Aug 14 '23 |
Sale |
8.89 |
576 |
5,123 |
484,801 |
Bickerstaff George | Director |
Aug 11 '23 |
Option Exercise |
5.09 |
19,453 |
99,065 |
99,721 |
Seeto Reginald | See Remarks |
Aug 02 '23 |
Sale |
11.35 |
2,819 |
31,988 |
486,051 |
Seeto Reginald | See Remarks |
Jul 13 '23 |
Sale |
10.33 |
5,260 |
54,357 |
488,870 |
Maag Peter | Director |
Jul 13 '23 |
Sale |
10.34 |
5,000 |
51,680 |
309,657 |
Seeto Reginald | See Remarks |
Jul 03 '23 |
Sale |
8.48 |
2,818 |
23,901 |
498,055 |
Seeto Reginald | See Remarks |
Jun 28 '23 |
Sale |
8.76 |
14,268 |
125,016 |
500,873 |
About Caredx Inc
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Cap:
|
Volume (24h):